louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03006406: Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Clinical Pregnancy Rate
Keywords: endometriosis
long term GnRH-a
Lead sponsor: The First Affiliated Hospital of Zhengzhou University
Sponsor class: OTHER
First posted: 2016-12-30
Enrollment: 50
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gonadotropin-releasing hormone analogue (GnRH-a) is a synthetic decapeptide compound which can down-regulate pituitary function causing a temporary low estrogen state. Since endometriosis is an estrogen-dependent disease, the use of long-acting GnRH-a can control the growth of endometriosis by inhibiting ovary function.Some scholars have found that, for adenomyosis patients who received a super long protocol (pretreatment of long-acting GnRH-a for 1-2 months) in IVF treatment, the pregnancy outcome is comparable to that of the controls with normal uterus. Thus, the aim of this study is to compare the clinical pregnancy rate in patients treated with GnRH-a for 1, or 2 months.


Eligibility criteria: Inclusion Criteria:

* first IVF cycle;
* with normal ovarian reserve(FSH(10miu/ml； antral follicle count )3)
* with normal uterine

Exclusion Criteria:

* Pre-implantation genetic diagnosis cycles;
* Oocyte donation cycles

Primary outcomes:
measure: clinical pregnancy rate
timeFrame: 5 weeks after embryo transfer
Secondary outcomes:
measure: Number of oocytes retrieved
timeFrame: 1 day at oocyte retrieved day
measure: 2 pronucleus(2PN)fertilization rate
timeFrame: 48hours after oocyte retrieved day
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University
state: Henan
Study officials:
References:
citation: van der Houwen LE, Mijatovic V, Leemhuis E, Schats R, Heymans MW, Lambalk CB, Hompes PG. Efficacy and safety of IVF/ICSI in patients with severe endometriosis after long-term pituitary down-regulation. Reprod Biomed Online. 2014 Jan;28(1):39-46. doi: 10.1016/j.rbmo.2013.09.027. Epub 2013 Oct 9.
citation: Mijatovic V, Florijn E, Halim N, Schats R, Hompes P. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol. 2010 Jul;151(1):62-5. doi: 10.1016/j.ejogrb.2010.02.047. Epub 2010 Apr 21.
citation: Kong H, Hu L, Nie L, Yu X, Dai W, Li J, Chen C, Bu Z, Shi H, Wu Q, Guan Y, Sun Y. A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with endometriosis: A protocol. Reprod Health. 2018 Dec 20;15(1):213. doi: 10.1186/s12978-018-0639-8.
Clinical trial NCT04233606: Influence of Osmotic Stimulation of Vasopressin on Autonomic Function
Official title: Influence of Osmotic Stimulation of Vasopressin on Autonomic Function
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Water Stress
Body Water Dehydration
Keywords: Vasopressin
Heart Rate Variability
Cardiovascular Function
Autonomic Function
Lead sponsor: University of North Carolina, Greensboro
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Participants will complete two trials under two different hydration states: isovolemic increase in plasma osmolality and isovolemic control (maintain normal plasma osmolality)
Primary purpose: OTHER

Brief summary: The regulation of total body water that defines human hydration status is a complex and dynamic process. Current methods of assessing hydration status (e.g. hematologic and urinary analyses) lack the ability to track changes in hydration status in real-time due to whole-body homeostatic physiologic processes required to maintain central pressure and cardiovascular function. This project will address this problem by assessing the relationship between autonomic function (measured using heart rate variability), a brain-derived process that regulates cardiovascular function, and changes in the hydration-mediated hormone vasopressin.


Eligibility criteria: Inclusion Criteria:

* Males and Females between the ages of 18 - 35

Exclusion Criteria:

* 1) evidence of clinically relevant diseases that may alter body water regulation (e.g., diabetes, kidney disease, metabolic disorders, cardiovascular disease, and other potential fluid balance covariates such as habitual use of non-steroidal anti-inflammatory drugs or serotonin reuptake inhibitors,

  2) previous surgery on the digestive tract that may impair the body's ability to normally regulate body water,

  3) regular drug treatment within the previous 15 days,

  4) actively attempting to gain or lose body weight,

  5) For female participants, testing will take place during the early follicular phase of their menstrual cycle (days 1-8) to maintain consistency in the hydration status measures as total body water fluctuates over the course of the menstrual cycle. Females who are currently using contraceptives (e.g., IUD) that limit the number of menstrual cycles occurring in a given year will be excluded from this study to ensure accuracy in the testing periods for this study.

Primary outcomes:
measure: Change in autonomic function
timeFrame: 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes of saline infusion period
Secondary outcomes:
Other outcomes:
Locations:
city: Greensboro
country: United States
facility: University of North Carolina at Greensboro
state: North Carolina
Study officials:
References:
Clinical trial NCT01010906: A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
Official title: An Open-label, 3-Part, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-7009
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-11-10
Enrollment: 60
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy matched control participants. The primary hypothesis is that the area under the curve (AUC) (0 to infinity) of vaniprevir for participants with mild, moderate, or severe hepatic insufficiency is similar to that observed in healthy matched controlled participants.


Eligibility criteria: Inclusion Criteria:

Hepatic Participants:

* Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
* Apart from hepatic insufficiency, is in good general health
* Has a diagnosis of chronic stable hepatic insufficiency
* Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7 to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency). Moderate and Severe participants must have had a 50% score of 2 or higher on at least one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the prestudy visit.

Healthy Matched Participants:

* Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
* Is in good health

Exclusion Criteria:

* Female is pregnant, lactating, expecting to become pregnant or donate eggs
* Has a history of stroke or seizures
* Has a history of cancer
* Is unable to refrain from the use of any prescription or non-prescription medication
* Consumes excessive amounts of alcohol or caffeinated beverages daily
* Has had surgery, donated blood or participated in another investigational study with in the last 4 weeks
* Is a regular user or past abuser of any illicit drug including alcohol

Primary outcomes:
measure: Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration
timeFrame: 0-48 hours postdose
Secondary outcomes:
measure: Maximum Concentration (Cmax) of Vaniprevir in Blood Plasma Following Single Dose Administration
timeFrame: 0-48 hours postdose
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06977906: Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes
Official title: Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Robotic-Assisted Radical Prostatectomy
Locally Advanced Prostate Cancer
Bladder Suspension
Keywords: Robotic-Assisted Radical Prostatectomy
Locally Advanced Prostate Cancer
Bladder Suspension
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 300
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective, single-center clinical trial. It aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer. The technique evaluates the impact of preserving the anterior peritoneum of the bladder on postoperative bladder descent and urinary control recovery. A retrospective analysis compares this modified approach with traditional anterior approach surgery, assessing differences in oncological outcomes, early functional recovery, and postoperative complication rates. The goal is to provide new theoretical foundations and technical support for the prevention and treatment of postoperative urinary incontinence.


Eligibility criteria: Inclusion Criteria:

1. prostate biopsy and clinical confirmation of high-risk prostate cancer (PSA \> 20 ng/mL, Gleason score ≥ 8, or cT stage ≥ T2c) followed by robotic-assisted radical prostatectomy
2. multiparametric MRI (mpMRI) with a 3.0 T scanner for prostate or pelvic scans performed within 30 days before the operation at our center
3. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1
4. Complete clinical and prostate biopsy pathological data.
5. General health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies.

Exclusion Criteria:

1. Presence of surgical contraindications.
2. refusal of enhanced mpMRI imaging.

Primary outcomes:
measure: rate of continence
timeFrame: 1 week, 1 month and 3 month after postoperative removal of the urinary catheter
measure: The degree of bladder descent
timeFrame: 1 month after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: first hospital affiliated of Fujian medical university
state: Fujian
Study officials:
References:
Clinical trial NCT05590806: The Effect of Ground and Unground Enamel on the Clinical Performance of Direct Composite Build-ups
Official title: The Effect of Ground and Unground Enamel on the Clinical Performance of Direct Composite Build-ups After Orthodontic Treatment: Five Years of Follow-up
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Trial of Labor; Failure
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2022-10-21
Enrollment: 24
Sex: ALL
Minimum age (years): 14
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Twenty-four patients participated in the study. Patients received direct composite build-ups for diastema closure.

Detailed description: The restorations were performed separately by grounding and ungrounding the enamel on the proximal surfaces in symmetrical teeth.

Eligibility criteria: Inclusion Criteria:

* good oral hygiene, no periodontal or pulpal disease, interarch tooth size discrepancies (Bolton discrepancy) after orthodontic treatment

Exclusion Criteria:

* uncontrollable parafunctions, insufficient or poor oral hygiene, periodontal or gingival disease

Primary outcomes:
measure: Success rate
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00826306: Comparison Of Video-based Versus Written Patient Education on Sunscreen
Official title: Comparison of Video-based Versus Written Patient Education on Sunscreen Behavior
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermatology Disease
Skin Cancer
Keywords: patient education
dermatology patient education
sunscreen
sunscreen education
skin cancer
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2009-01-22
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to compare the effect of video-based patient education with written instruction on subjects' adherence to sunscreen application.

Detailed description: We plan to conduct a randomized, controlled trial comparing the effect of video-based patient education with written instruction on subjects' adherence to sunscreen application.

Subjects randomized to the video-based education arm will be instructed to watch a video on the importance of sunscreen application and the proper technique of applying sunscreen. Subjects randomized to the written education arm will receive written information on the importance of sunscreen application and the proper technique of applying sunscreen. The contents of the video and the written educational materials will be comparable.

At the end of the study period, 3 months later, subjects will be interviewed via telephone regarding their sunscreen application behavior during the last month of the study period. Subjects will also be interviewed regarding their comprehension and attitude towards video-based and written education materials.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older at time of consent, may be men or women.
* Able to adhere to the study visit schedule and other protocol requirements.
* Capable of giving informed consent.

Exclusion Criteria:

* Non-English speaking individuals
* Individuals with a known allergy to sunscreens
* Individuals with a history of psoriasis, because phototherapy has been shown to be beneficial for their skin condition

Primary outcomes:
measure: Sunscreen application behavior.
timeFrame: 3 months
Secondary outcomes:
measure: Subjects' comprehension and attitude towards video-based and written education materials.
timeFrame: 3 months
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Department of Dermatology
state: California
Study officials:
affiliation: University of California, Davis
name: April W Armstrong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00164606: A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina
Official title: A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Child Abuse
Keywords: child maltreatment
child abuse
prevention
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-14
Enrollment: 14690
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: This is a population-based evaluation of the effectiveness of the Triple-P-Positive Parenting Program. Triple-P is a system of parenting programs with multiple levels that aims to provide parents with parenting skills and support.

Detailed description: Eighteen counties in the state of South Carolina will be randomized to the dissemination of the Triple-P system or to a waitlist control condition. University of South Carolina staff will train health care professionals in the nine dissemination counties to use the Triple-P parenting programs. Triple-P is a parenting program that uses a tiered system of interventions of increasing strength depending on parents' and children's differing needs, ranging from media and information-based strategies, to two levels of moderate-intensity intervention using a brief consultation format, to two more intensive levels of parent training and behavioral family intervention targeting parenting skills and other family adversity factors such as marital conflict, depression and high levels of parenting stress. The evaluation of the dissemination of Triple-P will rely on two methods: the analysis of aggregate data on child maltreatment, injuries and hospitalizations, and annual surveys of families to examining parenting education, practices, and child behavior.

Eligibility criteria: Inclusion Criteria:

* Counties in South Carolina

Primary outcomes:
measure: child maltreatment reports
measure: injury to children
Secondary outcomes:
Other outcomes:
Locations:
city: Columbia
country: United States
facility: University of South Carolina
state: South Carolina
Study officials:
affiliation: University of South Carolina
name: Ronald J Prinz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01694706: Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir
Official title: Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of a Single Oral Dose of 240 mg Faldaprevir in an Open-label, Randomised, Three-way Cross-over Trial in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2012-09-27
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to investigate the effect of food and of gastric pH increase on the relative bioavailability of faldaprevir.


Eligibility criteria: Inclusion criteria:

1. Healthy male and female subjects

Exclusion criteria:

1. Any relevant deviation from healthy condition

Primary outcomes:
measure: Faldaprevir: Area Under the Curve Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
timeFrame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h, 96h and 120h after drug administration
measure: Faldaprevir: Maximum Measured Concentration (Cmax)
timeFrame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h, 96h and 120h after drug administration
Secondary outcomes:
measure: Faldaprevir: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
timeFrame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h, 96h and 120h after drug administration
Other outcomes:
Locations:
city: Biberach
country: Germany
facility: 1220.59.1 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
Clinical trial NCT06382506: The Effect of Hazelnut Flour on Blood Glucose
Official title: Can Hazelnut Flour Added to Gluten-free Corn Flour in Different Amounts Cause Differences in Blood Glucose Fluctuations?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Celiac Disease
Blood Glucose
Flour Sensitivity
Keywords: Obesity
Celiac Disease
Blood glucose
Flour Sensitivity
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: One of the factors affecting human health is nutrition. The effects of foods on blood glucose are still under investigation. The Glycemic Index (GI), which is associated with many diseases today, is a value that measures the rate at which carbohydrate-containing foods raise blood glucose. It is thought that the loaves of bread produced will be a product with low GI value and can be consumed by celiacs and diabetics. It is aimed to investigate the effect of adding different amounts of hazelnut flour to bread recipes using gluten-free corn flour on blood glucose.


Eligibility criteria: Inclusion Criteria:

* The study group consisted of volunteer individuals aged between 18 and 35 years.
* The first blood glucose measurement was taken after at least 8 hours of fasting and any of the bread types were given to the participants for consumption.
* During the measurements, the volunteers were observed to avoid water, coffee, and any food intake and to avoid excessive exercise.

Exclusion Criteria:

* Pregnant,
* lactating women
* patients with physician-diagnosed chronic diseases

Primary outcomes:
measure: One loaf of bread was consumed each week and the study will continue for a month. Blood glucose measurements were performed with a glucometer at 0 (fasting), 15, 30, 45, 60, 90, and 120 minutes after each bread consumption.
timeFrame: Within research completion, an average of a month
Secondary outcomes:
measure: This classification as obese and normal-weight individuals was made with the BIA (Bioelectrical impedance analysis) method. This classification was understood by anthropometric measurements made in the first week.
timeFrame: Within research completion, an average of 1 week
Other outcomes:
Locations:
city: Trabzon
country: Turkey
facility: Avrasya University
Study officials:
References: